Parexel has become the latest CRO to be bought up as the industry continues its M&A bonanza.
Six years after Pfizer's landmark REMOTE trial, Parexel and Sanofi are revisiting the idea of using wearables in clinical trials.
Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer.
LabConnect has received a healthy $24.5 million in its first equity investment.
OmniComm Systems, which owns early-phase clinical trial electronic data capture software TrialOne, has nailed a major CRO deal worth $11.7 million.
How PAREXEL's New Ecosystem of Technology, Processes and Expertise is Transforming Drug Development
Probably hoping to help turn things around after clinical setbacks, microRNA biotech Regulus tapped the help of CRO Aptuit.
JSR made another major biotech deal to acquire mammalian cell line developer Selexis, planning to combine it with KBI.
WuXi Biologics is pricing its shares at HK$20.60, the top end of its marketing range, valuing the IPO at $510 million, Bloomberg reports.
SynteractHCR will leverage the GOG Foundation's network of 300 investigational sites to support gynecologic oncology studies.
Helomics is partnering with Pittsburgh Life Sciences Greenhouse to establish an incubator for diagnostics and precision medicine.
Outcome Health, a healthcare intelligence tech firm, has raised an outsize $500 million first round of funding, valuing it at $5.5 billion.